Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341(26):1966–1973. https://doi.org/10.1056/NEJM199912233412603..
DOI: 10.1056/NEJM199912233412603
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. https://doi.org/10.1111/j.1398-9995.2004.00772.x..
DOI: 10.1111/j.1398-9995.2004.00772.x
Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–678. https://doi.org/10.1111/j.1398-9995.2010.02522.x..
DOI: 10.1111/j.1398-9995.2010.02522.x
Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228. https://doi.org/10.1185/03007995.2011.620950..
DOI: 10.1185/03007995.2011.620950
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092..
DOI: 10.1056/NEJMoa1804092
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093..
DOI: 10.1056/NEJMoa1804093
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. https://doi.org/10.1016/S2213-2600(21)00322-2..
DOI: 10.1016/S2213-2600(21)00322-2
Canonica GW, Bartezaghi M, Marino R, Rigoni L. Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA - an observational, 2 phase, patient reported outcomes study. Clin Mol Allergy. 2015;13(1):10. https://doi.org/10.1186/s12948-015-0019-7..
DOI: 10.1186/s12948-015-0019-7
Solidoro P, Patrucco F, de Blasio F, Brussino L, Bellocchia M, Dassetto D et al. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Ther Adv Respir Dis. 2019;13:1753466619841274. https://doi.org/10.1177/1753466619841274..
DOI: 10.1177/1753466619841274
Humbert M, Bourdin A, Taillé C, Kamar D, Thonnelier C, Lajoinie A et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60(5):2103130. https://doi.org/10.1183/13993003.03130-2021..
DOI: 10.1183/13993003.03130-2021
Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. https://doi.org/10.1111/cea.13614..
DOI: 10.1111/cea.13614
Renner A, Marth K, Patocka K, Idzko M, Pohl W. Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics. Immun Inflamm Dis. 2021;9(3):624–627. https://doi.org/10.1002/iid3.434..
DOI: 10.1002/iid3.434
Carpagnano GE, Scioscia G, Buonamico E, Lacedonia D, Diaferia F, Capozza E et al. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management. Multidiscip Respir Med. 2022;17(1):797. Available at: https://www.researchgate.net/publication/358359986_Early_effectiveness_of_type-2_severe_asthma_treatment_with_dupilumab_in_a_real-life_setting_a_FeNO-driven_choice_that_leads_to_winning_management.https://www.researchgate.net/publication/358359986_Early_effectiveness_of_type-2_severe_asthma_treatment_with_dupilumab_in_a_real-life_setting_a_FeNO-driven_choice_that_leads_to_winning_management
Hoshino M, Akitsu K, Kubota K, Ohtawa J. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis. Allergol Int. 2022;71(4):490–497. https://doi.org/10.1016/j.alit.2022.05.010..
DOI: 10.1016/j.alit.2022.05.010
Pose K, Laorden D, Hernández N, Villamañán E, Quirce S, Domínguez-Ortega J. Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting. J Investig Allergol Clin Immunol. 2023;33(3):217–219. https://doi.org/10.18176/jiaci.0837..
DOI: 10.18176/jiaci.0837
Minagawa S, Araya J, Watanabe N, Fujimoto S, Watanabe J, Hara H et al. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP. BMC Pulm Med. 2022;22(1):258. https://doi.org/10.1186/s12890-022-02046-3..
DOI: 10.1186/s12890-022-02046-3
Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, Bourdin A. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138. https://doi.org/10.1111/CEA.12853..
DOI: 10.1111/CEA.12853
Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179. https://doi.org/10.1186/S12931-019-1138-3..
DOI: 10.1186/S12931-019-1138-3
Henriksen DP, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. https://doi.org/10.1080/20018525.2018.1536097..
DOI: 10.1080/20018525.2018.1536097
Ramonell RP, Iftikhar IH. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis. Lung. 2020;198(1):95–103. https://doi.org/10.1007/S00408-019-00310-8..
DOI: 10.1007/S00408-019-00310-8
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200. https://doi.org/10.1016/J.JACI.2018.08.031..
DOI: 10.1016/J.JACI.2018.08.031
He LL, Zhang L, Jiang L, Xu F, Fei DS. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis. Int Immunopharmacol. 2018;64:223–231. https://doi.org/10.1016/J.INTIMP.2018.08.031..
DOI: 10.1016/J.INTIMP.2018.08.031
Calzetta L, Matera MG, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol. 2019;15(6):517–520. https://doi.org/10.1080/17425255.2019.1621837..
DOI: 10.1080/17425255.2019.1621837
Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023;72(1):11–23. https://doi.org/10.1016/j.alit.2022.11.008..
DOI: 10.1016/j.alit.2022.11.008
Ito A, Miyoshi S, Toyota H, Suzuki Y, Uehara Y, Hattori S et al. The overlapping eligibility for bioligics in patients with severe asthma and phenotypes. Arerugi. 2022;71(3):210–220. https://doi.org/10.15036/arerugi.71.210..
DOI: 10.15036/arerugi.71.210
Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55(2):152–160. https://doi.org/10.1080/02770903.2017.1322611..
DOI: 10.1080/02770903.2017.1322611
Kimura Y, Suzukawa M, Inoue N, Imai S, Akazawa M, Matsui H. Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use. World Allergy Organ J. 2021;14(11):100600. https://doi.org/10.1016/j.waojou.2021.100600..
DOI: 10.1016/j.waojou.2021.100600
Akenroye A, Marshall J, Simon AL, Hague C, Costa R, Jamal-Allial A et al. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations. J Allergy Clin Immunol Pract. 2024;S2213-2198(24)00211–3. https://doi.org/10.1016/j.jaip.2024.02.034..
DOI: 10.1016/j.jaip.2024.02.034
Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed. 2005;7(1):27. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1681435/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1681435/
Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumab: what we still have to learn. Biologics. 2018;12:135–142. https://doi.org/10.2147/BTT.S180846..
DOI: 10.2147/BTT.S180846
Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11(12):958–972. https://doi.org/10.1038/nrd3792..
DOI: 10.1038/nrd3792
Manuyakorn W, Howarth PH, Holgate ST. Airway remodelling in asthma and novel therapy. Asian Pac J Allergy Immunol. 2013;31(1):3–10. Available at: https://pubmed.ncbi.nlm.nih.gov/23517388.https://pubmed.ncbi.nlm.nih.gov/23517388
Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023;151(5):1269–1276. https://doi.org/10.1016/j.jaci.2023.01.020..
DOI: 10.1016/j.jaci.2023.01.020
Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. https://doi.org/10.1016/j.jaci.2019.05.031..
DOI: 10.1016/j.jaci.2019.05.031
Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. https://doi.org/10.1164/rccm.200906-0896OC..
DOI: 10.1164/rccm.200906-0896OC
Mansur AH, Gonem S, Brown T, Burhan H, Chaudhuri R, Dodd JW et al. Biologic therapy practices in severe asthma; outcomes from the UK Severe Asthma Registry and survey of specialist opinion. Clin Exp Allergy. 2022;53(2):173–185. https://doi.org/10.1111/cea.14222..
DOI: 10.1111/cea.14222
Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814–830. https://doi.org/10.1016/j.chest.2021.04.013..
DOI: 10.1016/j.chest.2021.04.013
Baan EJ, de Roos EW, Engelkes M, de Ridder M, Pedersen L, Berencsi K et al. Characterization of Asthma by Age of Onset: A Multi-Database Cohort Study. J Allergy Clin Immunol Pract. 2022;10(7):1825–1834. https://doi.org/10.1016/j.jaip.2022.03.019..
DOI: 10.1016/j.jaip.2022.03.019
Deschildre A, Marguet C, Langlois C, Pin I, Rittié JL, Derelle J et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–859. https://doi.org/10.1183/09031936.00008115..
DOI: 10.1183/09031936.00008115
Licari A, Castagnoli R, Denicolò C, Rossini L, Seminara M, Sacchi L et al. Omalizumab in Childhood Asthma Italian Study Group. Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience. Curr Respir Med Rev. 2017;13(1):36–42. https://doi.org/10.2174/1573398X13666170426094536..
DOI: 10.2174/1573398X13666170426094536
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. https://doi.org/10.1016/j.jaci.2019.12.006..
DOI: 10.1016/j.jaci.2019.12.006
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. https://doi.org/10.1016/j.jaci.2019.12.006..
DOI: 10.1016/j.jaci.2019.12.006
Milger K, Korn S, Feder C, Fuge J, Mühle A, Schütte W et al. Criteria for evaluation of response to biologics in severe asthma – the Biologics Asthma Response Score (BARS). Pneumologie. 2023;77:220–232. https://doi.org/10.1055/a-2102-8128..
DOI: 10.1055/a-2102-8128
Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J et al. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort. J Allergy Clin Immunol Pract. 2023;11(9):2701–2712. https://doi.org/10.1016/j.jaip.2023.05.047..
DOI: 10.1016/j.jaip.2023.05.047